No products in the cart
Potential of GHRP-2 in Stimulating HGH Production
Pralmorelin (GHRP-2) is a synthetic peptide that stimulates growth hormone secretion by binding to the growth/ghrelin hormone secretagogue receptor.
Pralmorelin is the first human growth hormone secretion promoter to be introduced. It is marketed as a diagnostic peptide for growth hormone insufficiency and subsequent adrenal failure. Pralmorelin was accessed in stage II clinical trials for dwarfism assessment. Its effects on muscular growth, the immune system, hunger, and sleep cycles are still under study.
Primary Effects of Pralmorelin (GHRP-2)
● Muscle Structure Protection and Enhancement: According to a clinical study in Yaks, pralmorelin increases muscle growth in two ways: increased protein deposition and reduced protein degradation. Pralmorelin can aid in the treatment of natural growth plateaus caused by disease, poor environmental conditions, and food shortages. According to preliminary studies, Pralmorelin reduces muscle atrophy by inactivating atrogin-1 and MurRF1, two proteins involved in the muscle breakdown process. The researchers reported “GHRP-2 attenuated dexamethasone-induced expression of them dose-dependently and decreased the basal level of MuRF1 mRNA.” According to researchers, researchers, Pralmorelin may be useful in treating chronic diseases such as cancer and autoimmune disorders.
GHRP-2 can increase muscle protein deposition by activating growth hormone and insulin-like growth factor-1. Even in critical situations, the combined impact of lowering disintegration and increasing deposition allows for the formation of lean body mass.
● Pralmorelin’s Contribution to Immune System Improvement: According to studies, Pralmorelin stimulates the Thymus—an organ in the human immune system that defends certain cells. The thymus aids the development of T lymphocytes. T cells are adaptive immune cells that help the human body fight off complex infections. Thymic function diminishes with age, resulting in various age-related dysfunctions ranging from diminished immunity to inadequate tissue repair and the inability to fight infections, protect against cancer, and maintain normal tissue function. The peptide can rejuvenate the thymus, improving the kind and quantity of T cells generated. This will boost immunity.
● Pralmorelin Increases Appetite: According to studies, GHRP-2 may increase appetite and food consumption. The researchers report that “GHRP-2, like ghrelin, increases food intake, suggesting that GHRP-2 is a valuable tool for investigating ghrelin effects on eating behavior in humans.” This may look excessive in other conditions. In chronic sickness situations, food consumption is crucial to health treatment. This can help clinicians manage chronically ill individuals and improve long-term outcomes.
● GHRP-2 Improves Sleep Quality: Clinical studies show that Pralmorelin can extend the duration of stages 3 and 4 of the sleep cycle by roughly 50% and 20%, respectively, while decreasing the frequency with which a person deviates from normal sleep by around one-third. Pralmorelin helps with memory, healing, blood pressure, and vitality. Although these functions are vital in adults, they appear to be particularly critical in the elderly because aging processes may affect sleep quality.
Pralmorelin might aid researchers in determining ways to increase sleep quality and help people realize the advantages of a good night’s sleep.
● The Impact of Pralmorelin on Pain Perception: Previously, scientists thought that Pralmorelin reduced pain in osteoarthritic animal models by increasing growth hormone levels and mending wounded tissues. Some researchers suggest that Pralmorelin has a direct effect on pain perception.
The body has four opioid receptors. Some of these receptors mediate pain, while others control breathing and wakefulness and generate addiction. GHRP-2 is an opioid receptor agonist that specifically binds to opioid receptors implicated in sedation, pain relief, and addiction.
● Pralmorelin Protects the Heart: Clinical investigations in damaged heart cell culture lines reveal that Pralmorelin can protect heart cells by lowering heart cell apoptosis after a heart attack. Pralmorelin does this by decreasing blood circulation and, as a result, nutrition availability.
Studies on Hexarelin, a Pralmorelin analog, show that there may be specific peptides for these receptors.
Disclaimer: The products mentioned are not intended for human or animal consumption. Research chemicals are intended solely for laboratory experimentation and/or in-vitro testing. Bodily introduction of any sort is strictly prohibited by law. All purchases are limited to licensed researchers and/or qualified professionals. All information shared in this article is for educational purposes only.
- Hu, R., Wang, Z., Peng, Q., Zou, H., Wang, H., Yu, X., Jing, X., Wang, Y., Cao, B., Bao, S., Zhang, W., Zhao, S., Ji, H., Kong, X., & Niu, Q. (2016). Effects of GHRP-2 and Cysteamine Administration on Growth Performance, Somatotropic Axis Hormone and Muscle Protein Deposition in Yaks (Bos grunniens) with Growth Retardation. PloS one, 11(2), e0149461. doi:10.1371/journal.pone.0149461.
- Yamamoto, D., Ikeshita, N., Matsubara, T., Tasaki, H., Herningtyas, E. H., Toda, K., Iida, K., Takahashi, Y., Kaji, H., Chihara, K., & Okimura, Y. (2008). GHRP-2, a GHS-R agonist, directly acts on myocytes to attenuate the dexamethasone-induced expressions of muscle-specific ubiquitin ligases, Atrogin-1 and MuRF1. Life sciences, 82(9-10), 460–466. doi:10.1016/j.lfs.2007.11.019.
- Taub, D. D., Murphy, W. J., & Longo, D. L. (2010). Rejuvenation of the aging thymus: growth hormone-mediated and ghrelin-mediated signaling pathways. Current opinion in pharmacology, 10(4), 408–424. doi:10.1016/j.coph.2010.04.015.
- Laferrère, B., Abraham, C., Russell, C. D., & Bowers, C. Y. (2005). Growth hormone releasing peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men. The Journal of clinical endocrinology and metabolism, 90(2), 611–614. doi:10.1210/jc.2004-1719.
- Copinschi, G., Leproult, R., Van Onderbergen, A., Caufriez, A., Cole, K. Y., Schilling, L. M., Mendel, C. M., De Lepeleire, I., Bolognese, J. A., & Van Cauter, E. (1997). Prolonged oral treatment with MK-677, a novel growth hormone secretagogue, improves sleep quality in man. Neuroendocrinology, 66(4), 278–286. doi:10.1159/000127249.
- Zeng, P., Li, S., Zheng, Y. H., Liu, F. Y., Wang, J. L., Zhang, D. L., & Wei, J. (2014). Ghrelin receptor agonist, GHRP-2, produces antinociceptive effects at the supraspinal level via the opioid receptor in mice. Peptides, 55, 103–109. doi:10.1016/j.peptides.2014.02.013.
- Muccioli, G., Broglio, F., Valetto, M. R., Ghè, C., Catapano, F., Graziani, A., Papotti, M., Bisi, G., Deghenghi, R., & Ghigo, E. (2000). Growth hormone-releasing peptides and the cardiovascular system. Annales d’endocrinologie, 61(1), 27–31.
- Bodart, V., Bouchard, J. F., McNicoll, N., Escher, E., Carrière, P., Ghigo, E., Sejlitz, T., Sirois, M. G., Lamontagne, D., & Ong, H. (1999). Identification and characterization of a new growth hormone-releasing peptide receptor in the heart. Circulation research, 85(9), 796–802. doi:10.1161/01.res.85.9.796.
Dr. Usman (BSc, MBBS, MaRCP) completed his studies in medicine at the Royal College of Physicians, London. He is an avid researcher with more than 30 publications in internationally recognized peer-reviewed journals. Dr. Usman has worked as a researcher and a medical consultant for reputable pharmaceutical companies such as Johnson & Johnson and Sanofi.